Shell Asset Management Co. Has $1.03 Million Stake in Pfizer Inc. $PFE

Shell Asset Management Co. lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 54.8% during the third quarter, HoldingsChannel reports. The firm owned 40,506 shares of the biopharmaceutical company’s stock after selling 49,152 shares during the quarter. Shell Asset Management Co.’s holdings in Pfizer were worth $1,032,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Aberdeen Group plc lifted its stake in Pfizer by 11.3% in the third quarter. Aberdeen Group plc now owns 5,870,254 shares of the biopharmaceutical company’s stock valued at $144,849,000 after buying an additional 597,643 shares in the last quarter. GF Fund Management CO. LTD. raised its holdings in shares of Pfizer by 13.9% during the third quarter. GF Fund Management CO. LTD. now owns 158,049 shares of the biopharmaceutical company’s stock worth $4,027,000 after acquiring an additional 19,324 shares during the period. Cidel Asset Management Inc. lifted its position in Pfizer by 2.6% in the 3rd quarter. Cidel Asset Management Inc. now owns 78,767 shares of the biopharmaceutical company’s stock valued at $2,007,000 after acquiring an additional 1,990 shares in the last quarter. Murphy & Mullick Capital Management Corp lifted its position in Pfizer by 15.8% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 13,482 shares of the biopharmaceutical company’s stock valued at $333,000 after acquiring an additional 1,840 shares in the last quarter. Finally, MSH Capital Advisors LLC boosted its stake in Pfizer by 23.0% in the 3rd quarter. MSH Capital Advisors LLC now owns 53,682 shares of the biopharmaceutical company’s stock worth $1,368,000 after purchasing an additional 10,050 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have issued reports on the company. Bank of America dropped their price target on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. HSBC reissued a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Zacks Research cut Pfizer from a “hold” rating to a “strong sell” rating in a research note on Monday, January 26th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Finally, Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Pfizer has a consensus rating of “Hold” and a consensus price target of $28.00.

Pfizer Stock Up 0.4%

PFE stock opened at $27.58 on Tuesday. The company has a market cap of $156.78 billion, a price-to-earnings ratio of 20.28 and a beta of 0.47. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $27.94. The business has a 50 day moving average price of $25.84 and a two-hundred day moving average price of $25.23. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same quarter in the prior year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was down 1.2% compared to the same quarter last year. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. The ex-dividend date of this dividend is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.